Practice Management Committee Financial Interest Disclosures
Educational Content Development
The ASRS controls the content and production of this CME activity and attempts to ensure the presentation of balanced, objective information. In accordance with the Standards for Commercial Support established by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Retina Specialists requires all planners, content reviewers, faculty, and any others in a position to control the educational content (including the significant others of those mentioned) to disclose any relationship they or their co-authors have with commercial interests which may be related to their content.
All ASRS members presenting CME are required to disclose to the activity audience the following information prior to beginning their presentation:
- Any relevant financial relationships a CME presenter has had with commercial interests within the past 12 months.
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships."
Note: All planners and teachers are required to report financial disclosures, using the codes below.
Description of Financial Interest
Types of Relationships
A Advisory Board
B Board of Directions
C Consultant
EM Employee
F Founder
I Investigator
SP Speaker
SH Stockholder
O Other
Nature of Compensation
EQ Equipment (dept or practice)
G Grants
H Honoraria
IP Intellectual Property Rights
NC No Compensation Received
OB Other Financial Benefit
R Royalty
RG Residency or Fellowship Program Funding
S Salary
ST Stock
SO Stock Options
Financial Interest Disclosures (planners)
|
Margaret Chang, MD, MS |
|
|
Genentech - Roche |
A,C/H |
|
Sabin Dang, MD |
|
|
Regeneron |
C/H |
|
Geeta Lalwani, MD |
|
|
Ocugen |
A/SO |
|
Genentech Inc |
SP/H |
|
Regeneron |
A/H |
|
Novartis - Ophthalmology |
C/H |
|
Regeneron, Inc. |
A, C/H, G |
|
Allergan a Company by AbbVie |
C/H |
|
Zeiss |
C/H |
|
Allergan a Company by AbbVie |
EM/S |
|
Anton Orlin, MD |
|
|
Allergan Inc |
A/H |
|
Genentech Inc |
A/H |
|
Ankoor Shah, MD |
|
|
Novartis |
C/H |
|
Ocular Therapeutix |
C/H |
|
John T. Thompson, MD |
|
| Genentech Inc. | I/G |
| EHR Command Center | SH/NC |
| Ocutrx | SH/NC |
| Charles Wykoff, MD, PhD | |
| Regeneron Pharmaceuticals | C,I,SP/G,H |
| Genentech, Inc. | C,I/G,H |
| Alimera Sciences | I/G |
| Bayer | C,I/G,H |
| Clearside Biomedical, Inc. | C,I/G,H |
| ONL Therapeutics | C,SH/H,ST |
| Novartis | C,I/G,H |
| Apellis Pharmaceutical | I,C/G,H |
| Santen | I/G |
| EyePoint (formerly pSivida) | C/H |
| Adverum Biotechnologies, Inc. | I,C/G,H |
| Regenxbio Inc. | I,C/G,H |
| Kodiak Sciences | C,I/H,G |
| Opthea | I,C/G,H |
| Recens Medical | C,I,SH/H,G,SO |
| PolyPhotonix | C,SH/H,SO |
| IONIS Pharmaceuticals | I/G |
| Oxurion | C,I/G,H |
| Outlook Therapeutics | I/G |
| Iveric Bio (formerly Ophthotech) | C,I/G,H |
| Graybug Vision | I/G |
| Xbrane Biopharma | I/G |
| Chengdu Kanghong | C,I/H,G |
| Aldeyra Therapeutics | I,G |
| Aerie Pharmaceuticals | I/G |
| Takeda | C/H |
| Gemini Therapeutics | I/G |
| OccuRx | C/H |
| Opthea | C/H |
| Palatin | C/H |
| Bionic Vision Technologies | C/H |
| Thea Open Innovation | C/H |
| Verana Health | C/H |
| Neurotech Pharmaceuticals, Inc | I,G |
| Roche | C,I/G,H |
| NGM Biopharmaceuticals | C,I/G,H |
| Taiwan Liposome Company | I/G |
| LMRI | I/G |
| Boehringer Ingelheim | I/G |
| Gyroscope Therapeutics | C,I/G,H |
| Senju | I/G |
| Bausch & Lomb | C/H |
| Arctic Vision | C/H |
| Allergan | C/H |
| SAI MedPartners | C/H |
| PentaVision | C/H |
| Ocular Therapeutix | C/H |
| Visgenx | SH/SO |
| Arrowhead Pharmaceuticals | C/H |
| SamChunDang Pharm. | I/G |
| Kato DSRC | C/H |